Compare Stocks

Infoblox Inc. (Infoblox) is a United States-based company, which delivers Actionable Network Intelligence to enterprise, government and service provider customers across the world. The Company's products include core network services, such as domain name system (DNS), dynamic host configuration protocol (DHCP), Internet protocol address manager (IPAM) data documentation initiative (DDI); Private Cloud/Virtualization; Public/Hybrid Cloud; Reporting and Analytics, and Network Insight. Its products also include DNS, such as DNS Firewall, Advanced DNS Protection, Threat Insight and Active Trust, and network automation, such as NetMRI. Its solutions include information technology (IT) compliance and digital economy. It offers solutions for Microsoft and Infoblox, Internet protocol version 6 (IPv6) readiness and cybersecurity ecosystem. It supports offerings, such as Infoblox BloxCare Premium and Elite Maintenance programs, as well as its optional Technical Account Manager service.

inContact, Inc. (inContact) is a provider of cloud contact center software solutions. The Company provides a range of cloud contact center call routing, self-service and agent optimization solutions. The Company operates through two business segments: Software and Network connectivity. inContact's Software segment includes the services related to the delivery of its cloud contact center software solutions. Its Network connectivity segment includes the voice and data long distance services provided to customers. It offers its products and services to its customers in approximately five vertical markets, such as customer services and sales business process outsourcers (BPOs), retail and direct response, healthcare providers, utilities, and state and local Government. It provides software, which includes Automatic call distributing, Computer telephony integration, Interactive voice response with speech recognition, Outbound dialer, Screen recording and Interactive reporting tool.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.